Choosing the Right Option for You As with any other medication, its essential to get a professional medical evaluation before starting any GLP-1 drug
A licensed provider confirms eligibility during evaluation
#ObesityCare #GLP1 #GLP1Medications #PublicHealth #WeightStigma #HealthEquity #ObesityTreatment #PatientSupport #HealthcareAccess #ObesityResearch #PersonCentredCare #HealthInequalities Registered Dietitian | Obesity Care & Health Strategy | Behavioural Science in Digital Health | Behavioural Intervention Design | Clinical Innovation New consensus statement, out this week in The Lancet Diabetes & Endocrinology, from European Association for the Study of Obesity (EASO), The European Federation of the Associations of Dietitians (EFAD) and ECPObesity: "Nutritional, functional, and psychological considerations for incretin-based therapies in adults." Link in comments
But as GLP-1s rise in popularity, so do nicknames like Ozempic breasts and Ozempic face. Now, a new side effect has come to light: Ozempic vagina. It is not a medical diagnosis, but is colloquially used to refer to vaginal changes that may take place due to GLP-1s' impact on muscle mass, hormones and the gastrointestinal system
Insider was unable to find data that covers all of Canada
Semaglutide and Tirzepatide are FDA-approved for weight loss and are administered under the supervision of medical professionals
